A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-03-19
Target enrollment:
Participant gender:
Summary
This is a phase I/II, open-label, multicenter study . During the study, subjects will be
evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and
antitumor activity of HB0045. The phase I study will enroll up to 54 subjects with advanced
solid tumors who have progressed on or after standard of care therapy and for whom there is
no further treatment available that in the judgement of the patient's physician would be
beneficial. One cycle is defined as 21 days.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shanghai Huaota Biopharmaceutical Co., Ltd.
Collaborators:
Dana-Farber Cancer Institute Gabrail Cancer Center Research M.D. Anderson Cancer Center